On August 27, 2021, Kindred Biosciences, Inc., (KindredBio), was acquired by Elanco Animal Health Incorporated, (Elanco), pursuant to the merger of Knight Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Elanco (Merger Sub), with and into KindredBio, with KindredBio surviving the merger as a wholly owned subsidiary of Elanco (Merger). The Merger was effected pursuant to the previously announced Agreement and Plan of Merger, dated as of June 15, 2021 (as amended by the First Amendment, dated June 30, 2021 (the First Amendment), the Merger Agreement), by and among KindredBio, Elanco and Merger Sub. In connection with the consummation of the Merger, all of the members of KindredBio's board of directors resigned from the Board and from all committees of the Board on which such directors served, effective as of the Effective Time. These resignations were not a result of any disagreements between KindredBio and the former directors on any matter relating to KindredBio's operations, policies or practices. Upon consummation of the Merger on August 27, 2021, pursuant to the Merger Agreement, the directors of Merger Sub immediately prior to the Effective Time, consisting of David Pugh, Kathleen St. Louis and Jinee Majors, became the directors of KindredBio. Also in accordance with the terms of the Merger Agreement, at the Effective Time, the officers of KindredBio were effectively removed and replaced by the officers of Merger Sub, effective at the Effective Time.